Advertisement

International Journal of Hematology

, Volume 109, Issue 1, pp 131–131 | Cite as

Correction to: A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma

  • Shin-ichi FuchidaEmail author
  • Kazutaka Sunami
  • Morio Matsumoto
  • Hirokazu Okumura
  • Tohru Murayama
  • Toshihiro Miyamoto
  • Eichi Otsuka
  • Naohito Fujishima
  • Tohru Izumi
  • Shigehisa Tamaki
  • Yasushi Hiramatsu
  • Yoshiaki Kuroda
  • Chihiro Shimazaki
  • Koichi Akashi
  • Mine Harada
  • on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT)
Correction
  • 330 Downloads

Correction to: International Journal of Hematology  https://doi.org/10.1007/s12185-018-2543-y

In the original publication of this article, the “Conflict of interest” was published incorrectly. The corrected “Conflict of interest” is given below for your reading.

Conflict of interest Dr. Sunami reports grants from GlaxoSmithKline, Novartis, Janssen, Sanofi, MSD, Alexion Pharma, Daiichi-Sankyo, and Abbvie, and grants and personal fees from Ono pharmaceutical, Takeda pharmaceutical, Celgene, and Bristol-Myers Squibb. Dr. Matsumoto reports personal fees from Celgene, Janssen, Bristol-Myers Squibb, Ono Pharmaceutical, and Takeda Pharmaceutical. Dr. Okumura reports personal fees from Celgene. Dr. Murayama reports personal fees from Bristol-Myers Squibb, Celgene, Eisai, Janssen, Kyowa Hakko Kirin, Nippon Shinyaku, Novartis Pharma, Ono Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Sanofi, Siemens Healthcare Diagnostics, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Takeda Pharmaceutical, Mundipharma, Beckman Coulter, and Chugai Pharmaceutical. Dr. Miyamoto reports personal fees from Celgene. Dr. Shimazaki reports personal fees from Ono Pharmaceutical, Celgene, and Fujimoto Pharmaceutical. Dr. Akashi reports personal fees from Celgene and Janssen, grants from Nippon Kayaku, and grants and personal fees from Kyowa Hakko Kirin, Takeda Pharmaceutical, Shionogi, and Mochida Pharmaceutical. Dr. Harada reports personal fees from Celgene.

Copyright information

© The Japanese Society of Hematology 2018

Authors and Affiliations

  • Shin-ichi Fuchida
    • 1
    Email author
  • Kazutaka Sunami
    • 2
  • Morio Matsumoto
    • 3
  • Hirokazu Okumura
    • 4
  • Tohru Murayama
    • 5
  • Toshihiro Miyamoto
    • 6
  • Eichi Otsuka
    • 7
  • Naohito Fujishima
    • 8
  • Tohru Izumi
    • 9
  • Shigehisa Tamaki
    • 10
  • Yasushi Hiramatsu
    • 11
  • Yoshiaki Kuroda
    • 12
  • Chihiro Shimazaki
    • 1
  • Koichi Akashi
    • 6
  • Mine Harada
    • 13
  • on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT)
  1. 1.Department of HematologyJapan Community Health care Organization Kyoto Kuramaguchi Medical CenterKyotoJapan
  2. 2.National Hospital Organization Okayama Medical CenterOkayamaJapan
  3. 3.National Hospital Organization Nishigunma National HospitalShibukawaJapan
  4. 4.Toyama Prefectural Central HospitalToyamaJapan
  5. 5.Hyogo Cancer CenterAkashiJapan
  6. 6.Kyushu University HospitalFukuokaJapan
  7. 7.Oita Prefectural HospitalOitaJapan
  8. 8.Akita University HospitalAkitaJapan
  9. 9.Tochigi Cancer CenterUtsunomiyaJapan
  10. 10.Ise Red Cross HospitalIseJapan
  11. 11.Japanese Red Cross Society Himeji HospitalHimejiJapan
  12. 12.Hiroshima University HospitalHiroshimaJapan
  13. 13.Karatsu Higashimatsuura Medical AssociationKaratsuJapan

Personalised recommendations